Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Highlights from COMy

Arnon Nagler • 13 May 2022
COMy 2022
Multiple Myeloma Antibodies CAR-T

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, briefly discusses the excitement around the COMy 2022 meeting, and highlights some of the topics being presented. Prof. Nagler also discusses how the myeloma treatment landscape is advancing with the introduction of novel immunotherapies. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals